본문으로 건너뛰기
← 뒤로

Minimally required essential bio markers for lymphoma.

Bioinformation 2026 Vol.22(1) p. 333-337

Ghanghoria S, Ghanghoria A, Sai Chownika GP, Thakur A, Verma TP, Parmar S

📝 환자 설명용 한 줄

Lymphoma is a diverse group of blood cancers arising from lymphoid tissue, characterized by distinct morphological, immunophenotypic, genetic and clinical variations.

이 논문을 인용하기

BibTeX ↓ RIS ↓
APA Ghanghoria S, Ghanghoria A, et al. (2026). Minimally required essential bio markers for lymphoma.. Bioinformation, 22(1), 333-337. https://doi.org/10.6026/973206300220333
MLA Ghanghoria S, et al.. "Minimally required essential bio markers for lymphoma.." Bioinformation, vol. 22, no. 1, 2026, pp. 333-337.
PMID 41960458

Abstract

Lymphoma is a diverse group of blood cancers arising from lymphoid tissue, characterized by distinct morphological, immunophenotypic, genetic and clinical variations. Therefore, it is of interest to identify which immunohistochemical (IHC) markers were minimum essentials markers to enable classification and prognostication in lymphoid malignancies. The retrospective study used a primary panel of monoclonal antibodies consisting of CD3 and CD5, CD20, CD10, CD45, PAX-5 and Ki-67 on 88 lymphoma cases. It was found that B-cell lymphomas were highly labeled with CD20, CD45, PAX-5, whereas T-cell lymphomas were heavily labeled with CD3, CD5. There were high levels of Ki-67 proliferation indices in the aggressive lymphoma sub-types e.g. Diffuse Large B-Cell Lymphoma and T-cell lymphomas. The study helps to recommend a restricted yet cost-effective panel of IHC markers to attain reliable diagnosis and prognosis of lymphoma particularly in lower resource settings.